Head-to-head comparison
| Property | Orforglipron | Semaglutide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| Legal Status | Research Only | Prescription |
| Primary Route | oral | subcutaneous |
| Half-life | 25-68 hours (single dose: 24.6-35.3h; steady state: 48.1-67.5h); supports once-daily dosing | ~7 days |
| Mol. Weight | 882.97 Da | 4,113.58 Da |
| Side Effects | Nausea, Vomiting, Diarrhea | Nausea (39%), Vomiting, Diarrhea |
Key differences
- Chemical class: Orforglipron is a small-molecule non-peptide GLP-1 agonist; semaglutide is a 31-amino-acid GLP-1 receptor agonist peptide.
- Administration: Orforglipron is a once-daily oral pill; semaglutide is primarily a once-weekly subcutaneous injection (Rybelsus oral form has lower bioavailability).
- Weight loss efficacy: Phase III ATTAIN-1 showed orforglipron (50 mg) achieved approximately 8.6% weight loss at 26 weeks; semaglutide (2.4 mg) achieved 15–17% over 68 weeks in STEP trials.
- Dosing frequency: Orforglipron is dosed once daily; injectable semaglutide is dosed once weekly.
- Manufacturing cost: Small molecules are generally cheaper to manufacture at scale than peptides, which could make orforglipron more affordable.
- Approval status: Orforglipron is in Phase III trials (Eli Lilly); semaglutide is FDA-approved with multiple indications (Novo Nordisk).
- Temperature storage: Orforglipron as a pill does not require refrigeration; injectable semaglutide requires cold chain storage before first use.
The verdict
Orforglipron's primary advantage is convenience — a daily pill versus a weekly injection — plus potential manufacturing cost savings as a small molecule. However, semaglutide has substantially more weight loss efficacy data (15–17% vs approximately 8.6% at shorter duration), FDA approval, and years of real-world safety experience. Orforglipron may expand the GLP-1 market to patients who refuse injections, but it may not match injectable semaglutide's efficacy ceiling. The two may ultimately serve complementary roles.
Frequently asked questions
Current Phase III data suggests orforglipron produces less weight loss than injectable semaglutide at maximum doses (approximately 8.6% at 26 weeks vs 15–17% at 68 weeks). However, trial durations differ and longer orforglipron studies may show additional loss. Orforglipron's value proposition is oral convenience, not necessarily superior efficacy.
Orforglipron is in Phase III clinical trials by Eli Lilly with results expected in 2025–2026. If approved, it would be the first non-peptide oral GLP-1 agonist. Specific approval timelines are not confirmed.
No, orforglipron is a small-molecule non-peptide compound that activates the GLP-1 receptor. Unlike semaglutide (a peptide), it does not require special handling or refrigeration and has high oral bioavailability without the absorption enhancers needed by oral semaglutide (Rybelsus).
Small molecules are generally cheaper to manufacture than peptides, so orforglipron could have lower production costs. Whether this translates to lower consumer pricing depends on market dynamics, insurance coverage, and Eli Lilly's pricing strategy. No pricing has been announced.
The ATTAIN-MAINTAIN trial studied orforglipron as maintenance therapy after tirzepatide induction, suggesting Lilly envisions sequential use. Switching from semaglutide to orforglipron would be a physician-guided decision once orforglipron is approved.